Grail shares hit new all-time highs after FDA advisers voted to recommend approval of the Galleri cancer test. Reported price targets stood at 148, 166 and 196, underscoring the market’s reassessment of the stock.
published
Grail shares hit new all-time highs after FDA advisers voted to recommend approval of the Galleri cancer test. Reported price targets stood at 148, 166 and 196, underscoring the market’s reassessment of the stock.
Latest documented BWB result
See Billy's timestamped results and follow-through.
Review the latest gains posts, original timestamps, and proof images published by Banking With Billy.
Historical results are not a promise of future performance. Trading involves substantial risk.This public post is a timestamped information archive, not personalized financial advice. Alerts can change as markets move. Join Billy's private group for the complete daily stream and follow-through.